Gene Therapy

Two drugs in the pipeline representing unique marketing challenges

Two drugs in the pipeline representing unique marketing challenges

By

Two touted products in the pipeline reflect three of medical marketing's most profound modern-era challenges.

Five things for pharma marketers to know: Tuesday, January 30, 2018

Five things for pharma marketers to know: Tuesday, January 30, 2018

By

Amazon, Berkshire Hathaway, and JPMorgan team up to form a healthcare company; Takeda's Zika vaccine receives FDA fast-track status

Five things for pharma marketers to know: Tuesday, January 23, 2018

Five things for pharma marketers to know: Tuesday, January 23, 2018

By

FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW

Five things for pharma marketers to know: Tuesday, January 16, 2018

Five things for pharma marketers to know: Tuesday, January 16, 2018

By By

Merck's Keytruda combo therapy succeeds in Phase-III lung cancer trial; FDA launches pilot to address trial transparency; Spark's Luxturna overpriced, ICER says

Five things for pharma marketers to know: Friday, January 12, 2018

Five things for pharma marketers to know: Friday, January 12, 2018

By

Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds

Five things for pharma marketers to know: Thursday, January 4, 2018

Five things for pharma marketers to know: Thursday, January 4, 2018

By

Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy

Five things for pharma marketers to know: Wednesday, December 20, 2017

Five things for pharma marketers to know: Wednesday, December 20, 2017

By

Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease

Five things for pharma marketers to know: Tuesday, July 18, 2017

Five things for pharma marketers to know: Tuesday, July 18, 2017

By

Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy

Five things for pharma marketers to know: Thursday, May 11, 2017

Five things for pharma marketers to know: Thursday, May 11, 2017

By

FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs

Five things for pharma marketers to know: Thursday, April 20, 2017

Five things for pharma marketers to know: Thursday, April 20, 2017

By

Tesaro discloses price for new drug that differs from FDA-approved dosage; uniQure discontinues Glybera; O'Reilly leaves Fox

Five things for pharma marketers to know: Thursday, September 1, 2016

Five things for pharma marketers to know: Thursday, September 1, 2016

By

Novartis to fold its cell and gene therapy business; Novo Nordisk CEO to retire; the FDA issues a safety warning for opioids taken with anti-anxiety drugs

Five things for pharma marketers to know: Monday, November 16, 2015

Five things for pharma marketers to know: Monday, November 16, 2015

By

PBMs crack down on specialty pharmacies; Merck's cholesterol drug soldiers on; rare-disease drug nabs approval

Five things for pharma marketers to know: Monday, June 15

Five things for pharma marketers to know: Monday, June 15

By

CVS Health to buy Target's pharmacy business; experimental gene therapy improves condition of teen with sickle-cell disease; PatientsLikeMe partners with the FDA to improve postmarket surveillance